# Clear Labs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clear-labs

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.clearlabs.com
- Total disclosed funding: $148M
- Latest round: Series D (Dec 12, 2024)
- Investors on record: 16

## About

Founded in 2014 and based in California, US, Clear Labs, Inc. operates as a provider of molecular food analytics platforms that analyze the molecular contents of foods and ingredients. The company’s former name is Genestamp.Inc. and its turnkey platform accelerate outcomes and improve accuracy from food-borne pathogens to infectious diseases, including SARS-CoV-2. Mahni Ghorashi and Sasan Amini are the co-founders of the company. In May 2021, the firm raised USD 60 million in Series C funding co-led by Morgan Stanley Counterpoint Global and T. Rowe Price. In December 2024, Clear Labs, Inc. raised USD 29.06 million in series D funding from returning investors Felicis Ventures, GV, HBM Genomics, Khosla Ventures, Menlo Ventures, Morgan Stanley Counterpoint Global, Nimble Ventures, Redmile Group, T Rowe Price, and Wings Capital Ventures.


The company provides clinical testing and food safety testing products. Clear Dx™ is a fully automated, next-generation sequencing platform that offers a complete characterization of SARS-CoV-2 and its variants of concern. It is built to deliver accurate and near real-time results. Clear Safety™ enables deep molecular characterization of pathogens, with just the amount of information needed for the safety program. 

Clear Labs plan to use the May 2021 funding to increase the availability of the company's solutions to public health organizations, reference labs, hospitals, and epidemiologists.

## Funding rounds

- Series D, Dec 12, 2024, $29M — Menlo Ventures, Morgan Stanley Investment Management, T Rowe Price, Khosla Ventures, GV, Felicis Ventures, Redmile Group, Wing, HBM Genomics, Nimble Ventures
- Series C, May 13, 2021, $60M — Menlo Ventures, Morgan Stanley Investment Management, T Rowe Price, Khosla Ventures, GV, Felicis Ventures, Redmile Group, Wing, HBM Genomics, Dafgårds
- Series B, May 18, 2020, $20M — Menlo Ventures, Khosla Ventures, GV, Felicis Ventures, Redmile Group, Wing, Dentsu Ventures, Tyson New Ventures, HBM Genomics
- Series B, Oct 24, 2018, $19M — Menlo Ventures, Khosla Ventures, Felicis Ventures, Wing, Dentsu Ventures
- Series B, Dec 7, 2016, $13M — Khosla Ventures, GV, Felicis Ventures, Tencent Investment, Wing
- Series A, Aug 31, 2015, $6.2M — Khosla Ventures, Felicis Ventures, Plug and Play, SGH Capital, Nimble Ventures

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series A, Series B, Series C, Series D
- Felicis Ventures (https://capitalatlas.ai/funds/felicis-ventures) — Series A, Series B, Series C, Series D
- Plug and Play (https://capitalatlas.ai/funds/plug-and-play) — Series A
- SGH Capital (https://capitalatlas.ai/funds/sgh-capital) — Series A
- Nimble Ventures (https://capitalatlas.ai/funds/nimble-ventures) — Series A, Series D
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C, Series D
- Tencent Investment — Series B
- Wing (https://capitalatlas.ai/funds/wing) — Series B, Series C, Series D
- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series B, Series C, Series D
- Dentsu Ventures (https://capitalatlas.ai/funds/dentsu-ventures) — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B, Series C, Series D
- Tyson New Ventures (https://capitalatlas.ai/funds/tyson-new-ventures) — Series B
- HBM Genomics (https://capitalatlas.ai/funds/hbm-genomics) — Series B, Series C, Series D
- Morgan Stanley Investment Management — Series C, Series D
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C, Series D
- Dafgårds — Series C